Company / Shareholders' Equity
Bio-Rad Laboratories Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$7.5B
FY2025
5-year range
$6.6B / $13.7B
FY2021-FY2025
Trend
+13.5%
vs FY2024
Sector context
#21 of 161
Health Care
What the data says
Bio-Rad Laboratories's shareholders' equity of $7.5B is higher than 87% of companies in the Health Care sector (FY2025). Shareholders' Equity returned to growth in FY2025 after 3 years of decline, reaching $7.5B.
Based on SEC 10-K filings.
$7.5B in FY2025 with a 5-year CAGR of +13.1%. Top quartile in the Health Care sector.
Declined from $8.7B to $7.5B over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -8.1%
- 5-Year CAGR
- +13.1%
- 10-Year CAGR
- -
Sector benchmark
+47.2% above sector average
Key checks
Key Insights
- 5-year CAGR of +13.1%, indicating consistent growth.
- In FY2025, shareholders' equity increased 13.5% year-over-year.
- Ranks #21 out of 161 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2021.
Company context
Key Data Points
- Strong return on equity: 23.0%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.5B | +13.5% |
| FY2024 | $6.6B | -24.8% |
| FY2023 | $8.7B | -9.1% |
| FY2022 | $9.6B | -29.7% |
| FY2021 | $13.7B | +240.4% |
| FY2020 | $4.0B | -30.2% |
| FY2019 | $5.8B | +123.2% |
| FY2018 | $2.6B | +3.8% |
| FY2017 | $2.5B | +13.7% |
| FY2016 | $2.2B | -12.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026